Choo, R., Klotz, L., Deboer, G., Danjoux, C. and Morton, G.: Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. BJU International, 94: 295, 2004
Laird, N. M., Ware, J. H.: Random-effects models for longitudinal data. Biometrics, 38: 963, 1981
Littrup PJ, Lee F, Mettlin C. Prostate Cancer Screening: Current Trends and Future Implications. CA-Cancer J Clin 1992;42:199-211.
Patel, A., Dorey, F., Franklin, J. and deKernion, J. B.: Recurrence patterns after radical retropublic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol, 158: 1441, 1997
Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
Smith PH. The case for no initial treatment of localized prostate cancer. Uro Clin NA. 1990;17:827-834.
Verbeke, G.: Linear mixed models for longitudinal data. In: Verbeke G, Molenberghs G, editors. Linear mixed models in practice: A SAS-oriented approach. 1st ed. New York: Springer, 63-153, 1997
Zhang L, Loblaw A, Klotz L. Modelling PSA kinetics in patients on active surveillence. J Urol 176: 1392-8, 2006.
